Morgan Stanley Downgrades RXO to Equal-Weight, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 54.7%

Neg 54.7% Neu 0% Pos 0%

Morgan Stanley analyst Ravi Shanker downgrades RXO (NYSE:RXO) from Overweight to Equal-Weight and raises the price target from $19 to $22.